S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Israel is quiet on next steps against Iran — and on which partners helped shoot down missiles
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Israel is quiet on next steps against Iran — and on which partners helped shoot down missiles
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Israel is quiet on next steps against Iran — and on which partners helped shoot down missiles
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Israel is quiet on next steps against Iran — and on which partners helped shoot down missiles
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
NASDAQ:MYNZ

Mainz Biomed (MYNZ) Stock Price, News & Analysis

$0.97
-0.03 (-3.00%)
(As of 04/12/2024 ET)
Today's Range
$0.97
$1.04
50-Day Range
$0.88
$1.15
52-Week Range
$0.85
$6.10
Volume
77,933 shs
Average Volume
52,084 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Mainz Biomed MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
518.6% Upside
$6.00 Price Target
Short Interest
Healthy
2.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.23mentions of Mainz Biomed in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.04 out of 5 stars

MYNZ stock logo

About Mainz Biomed Stock (NASDAQ:MYNZ)

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.

MYNZ Stock Price History

MYNZ Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
EQS-News: Mainz Biomed Reports Full Year 2023 Financial Results
Mainz Biomed (NASDAQ:MYNZ) Shares Up 0.9%
Mainz Biomed (NASDAQ:MYNZ) Trading Up 0.9%
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
MYNZ Mainz Biomed N.V.
See More Headlines
Receive MYNZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/15/2023
Today
4/14/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MYNZ
Fax
N/A
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$9.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+518.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$900,000.00
Book Value
$1.17 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.24
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Guido Baechler (Age 59)
    CEO & Director
  • Mr. William J. Caragol (Age 57)
    Chief Financial Officer
  • Dr. Chris Von Torne P.M.P.
    Ph.D., Chief Operating Officer
  • Dr. Frank Krieg-Schneider
    Chief Technology Officer
  • Dr. Moritz Eidens Ph.D. (Age 40)
    Chief Science Officer & Director
  • Stefan Erlach
    Head of Human Resources
  • Mr. Philipp Freese (Age 41)
    C.B.O.
  • Mr. Darin S. Leigh (Age 56)
    Chief Commercial Officer

MYNZ Stock Analysis - Frequently Asked Questions

Should I buy or sell Mainz Biomed stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mainz Biomed in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MYNZ shares.
View MYNZ analyst ratings
or view top-rated stocks.

What is Mainz Biomed's stock price target for 2024?

2 brokerages have issued 1-year price objectives for Mainz Biomed's shares. Their MYNZ share price targets range from $3.00 to $9.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 518.6% from the stock's current price.
View analysts price targets for MYNZ
or view top-rated stocks among Wall Street analysts.

How have MYNZ shares performed in 2024?

Mainz Biomed's stock was trading at $1.16 at the beginning of the year. Since then, MYNZ shares have decreased by 16.4% and is now trading at $0.97.
View the best growth stocks for 2024 here
.

When is Mainz Biomed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our MYNZ earnings forecast
.

How were Mainz Biomed's earnings last quarter?

Mainz Biomed (NASDAQ:MYNZ) announced its earnings results on Tuesday, August, 15th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.14. The business had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.25 million.

When did Mainz Biomed IPO?

Mainz Biomed (MYNZ) raised $10 million in an initial public offering on Friday, November 5th 2021. The company issued 2,000,000 shares at $4.00-$6.00 per share. Boustead Securities acted as the underwriter for the IPO.

How do I buy shares of Mainz Biomed?

Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MYNZ) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners